Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30225262 | 1.00 | SYK (0.42) | SYKSPRHDAC1HDAC8HDAC6 | |
| SCHEMBL23986869 | 0.92 | SYK (0.41) | SYKSPRHDAC1HDAC8HDAC6 | |
| SCHEMBL30225205 | 0.90 | SYK (0.40) | SYKSPRHDAC1HDAC8HDAC6 | |
| SCHEMBL23975961 | 0.90 | SYK (0.40) | SYKSPRHDAC1HDAC8HDAC6 | |
| SCHEMBL30118704 | 0.89 | SYK (0.39) | SYKSPRHDAC1HDAC8HDAC6 | |
| SCHEMBL23976359 | 0.89 | SYK (0.39) | SYKSPRHDAC1HDAC8HDAC6 | |
| SCHEMBL23976078 | 0.88 | SYK (0.42) | SYKSPRPDE10AMAPT | |
| SCHEMBL23975850 | 0.88 | SYK (0.40) | SYKHDAC1HDAC8HDAC6PDE10A | |
| SCHEMBL23976639 | 0.88 | SYK (0.42) | SYKSPRPDE10AMAPT | |
| SCHEMBL30118630 | 0.88 | SYK (0.42) | SYKSPRPDE10AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | SYK 3681/4885SPR 273/4885HDAC1 4619/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | SYK 4185/4885SPR 377/4885HDAC1 4175/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | SYK 4185/4885SPR 377/4885HDAC1 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.